Effect of a polyherbal formulation in streptozotocin-induced diabetic nephropathy in wistar rats.
| Autor: | Reddy KS; Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India., Sudheer A; Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India., Pradeepkumar B; Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India., Reddy CS; Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of pharmacology [Indian J Pharmacol] 2019 Sep-Oct; Vol. 51 (5), pp. 330-336. Date of Electronic Publication: 2019 Nov 26. |
| DOI: | 10.4103/ijp.IJP_217_18 |
| Abstrakt: | Objectives: Chronic kidney failure among people with diabetes mellitus (DM) is a burgeoning health problem that affects up to 25% of patients with type 2 DM. Current pharmacological treatment for diabetic nephropathy (DN) does not stop the attainment of renal complications. The intention of the current study was to explore the role of a polyherbal formulation (PHF) in diabetic-induced nephropathy in experimental animals. Materials and Methods: Diabetic rats were grouped as follows and underwent the following treatment for about 16 weeks: Group I - normal rats - no treatment, Group II - DN rats - only vehicle (p.o), and Group III and IV - DN rats - PHF orally at 250 and 500 mg/kg, respectively. After the treatment, the animals were sacrificed, and lipid, renal function, and inflammatory markers were estimated. The observed microscopic changes in kidney were analyzed. Results: Animals administered with PHF exhibited noteworthy decrease in triglycerides, total cholesterol, very low-density lipoprotein (LDL), LDL, serum creatinine, urinary protein, urinary albumin excretion rate, advanced glycation end products, type IV collagen excretion, interleukin-6, transforming growth factor-ß, and tumor necrosis factor-alpha and showed significant increase in high-density lipoprotein, urine volume, urinary urea, and urine creatinine. Histopathological examination established that administration of PHF prohibited kidney damage. Conclusion: Treatment with PHF showed beneficial effect on DN which may be due to the improvement of renal function parameters and hyperlipidemic and inflammatory mediators. Competing Interests: There are no conflicts of interest. (Copyright: © 2019 Indian Journal of Pharmacology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|